NCT03466320已完成1 期
An Open-label, Phase I/II Study to Assess the Safety and Clinical Activity of NKR-2 Treatment Administration After a Non-myeloablative Preconditioning Chemotherapy in Relapse/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 12
- 主要终点
- The occurrence of Dose-limiting toxicities (DLT) during the study treatment until 3 weeks after first NKR-2 study treatment administration.
研究概览
简要总结
This open-label Phase I study aims at assessing primarily the safety of the NKR-2 treatment administered after a non-myeloablative preconditioning regimen in r/r AML/MDS patients.
This Phase I study will contain two different sequential segments. The first segment will determine the recommended investigational treatment option (schedule of preconditioning and NKR-2 dose) and the second segment will expand to a larger number of r/r AML/MDS patients.
详细描述
This open-label Phase I/II study aims at assessing primarily the safety and the clinical activity of the NKR-2 treatment administered after a non-myeloablative preconditioning regimen in r/r AML/MDS patients.
The Phase I part of the study will contain two different sequential segments. The first segment (dose escalation segment) will determine the recommended investigational treatment option (schedule of preconditioning and NKR-2 dose) and the second segment (extension segment) will expand to a larger number of r/r AML/MDS patients.
The Phase II part of the study will also contain two sequential segments, assessing the clinical activity of the NKR-2 treatment administrated as per the recommended investigational treatment option (schedule of preconditioning and NKR-2 dose).
The Phase I dose escalation segment will evaluate the preconditioning regimen consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily (CYFLU) administrated 3 consecutive days at a specific interval prior to the NKR 2 administration. This segment is divided into four sequential cohorts to evaluate respectively:
- Two different intervals between the preconditioning regimen and the NKR-2 administration i.e. NKR-2 administered 3 days (T3) or 7 days (T7) after the end of the preconditioning regimen,
- Three different NKR-2 dose-levels i.e. dose-level 1 (1x108 NKR 2/injection), dose-level 2 (3x108 NKR-2/injection) and dose-level 3 (1x109 NKR-2/injection).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient must have signed the written ICF and must accept that, beyond the treatment period, and the treatment follow-up period, he/she will have to be monitored for a Long-Term Safety Follow-Up (LTSFU) for up to 15 years after enrollment.
- •Both men and women of all races and ethnic groups are eligible.
- •The patient must be ≥ 18 and ≤ 75 years old at the time of signing the ICF.
- •The patient must not be eligible for standard of care therapy and have one of the following hematological malignancy:
- •4.a. A confirmed relapsed or refractory acute myeloid leukemia (AML) (i.e. ≥ 5% blasts in bone marrow or in peripheral blood) after at least one prior therapy defined as either
- •Recurrence of disease after a first complete remission (CR1) and not eligible for a second course of induction therapy, or
- •Recurrence of disease after a second complete remission (CR2), or
- •Failure to achieve CR after induction chemotherapy. Note: Patient with AML M3 are excluded. 4.b. A confirmed myelodysplastic syndrome (MDS) with:
- •Revised International Prognostic Scoring System (R-IPSS) criteria for Intermediate, High-risk or Very High-risk disease or refractory anemia with excess blasts by WHO (i.e. ≥ 5% blasts in bone marrow or ≥ 2% blasts in peripheral blood) or MDS with TP53 mutation as detected by next-generation sequencing (NGS).
- •Failure of prior treatment with at least 4 cycles of azacitidine or decitabine defined as no response to treatment, loss of response at any time point, or progressive disease/intolerance to therapy.
- •The absolute peripheral blast count should be < 15,000/L.
- •The patient must have evaluable disease defined by:
- •Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, for AML patients,
- •IWG 2006 Uniform Response Criteria for patients with Higher-Risk MDS.
- •The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status below or equal to
- •The patient must have adequate hepatic and renal functions as assessed by standard laboratory criteria
- •The patient must have a left ventricular ejection fraction (LVEF) of more than or equal to 40%, as determined by echocardiography or a multigated acquisition (MUGA) scan.
- •The patient must have a good pulmonary function with a Forced Expiratory Volume in the first second (FEV-1)/Forced Vital Capacity (FVC) more than or equal to 0.7 with FEV-1 more than or equal to 50% predicted (GOLD 1 or 2 severity) as determined by the spirometry performed at baseline , unless related to the AML/MDS disease as judged by the Investigator.
- •Women of child-bearing potential and men must agree to use effective contraception before, during and for at least 2 months after the last study treatment administration.
- •The patient must, in the opinion of the Investigator, be able to adhere with the study visit schedule and all study procedures described in this protocol.
排除标准
- •The patient has a confirmed or history of tumor involvement in the central nervous system (CNS).
- •Patients who have received any cancer therapy (investigational agent or not), including but not limited to chemotherapy, small molecules, monoclonal antibodies (e.g., immune checkpoint blockade therapies), or radiotherapy within 2 weeks before the planned day for the apheresis (Day -21)
- •Patients who are planned to receive, concurrently receiving or have received any investigational agent within 3 weeks before the planned day for the first NKR-2 administration (Day 1).
- •Patient is under systemic immunosuppressive drugs, unless specific cases authorized per protocol.
- •Patients who have received prior allogeneic stem cell transplantation or chimeric antigen receptor therapy.
- •Patients who are presenting persistent toxicities greater than or equal to CTCAE grade 2 caused by previous cancer therapy (except for clinically non-significant toxicities, such as alopecia).
- •Presence of any indwelling catheter or drain (e.g., percutaneous nephrostomy tube, indwelling foley catheter, biliary drain, or pleural/peritoneal/pericardial catheter) may be permissible unless they have a catheter-associated infection that cannot be cleared with antibiotics. Ommaya reservoirs and dedicated central venous access catheters such as a Port-a-Cath, peripherally inserted central catheter, or Hickman catheter are permitted.
- •Patients who underwent major surgery within 4 weeks before the planned day for the first NKR-2 administration (Day 1).
- •Patients who have received a live vaccine ≤ 6 weeks prior to each NKR 2 administration.
- •Patients with uncontrolled intercurrent illness or serious uncontrolled medical disorder including, but not limited to evidence of active pneumonitis on screening chest imaging, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia history (or evidenced after the electrocardiogram planned at screening) and/or pronounced disturbances of the electrical conduction system of the heart, or significant thromboembolic events.
- •Patients with significant disorder of coagulation or receiving treatment with warfarin derivatives or heparin.
- •Patients who have active infections including, but not limited to viral, bacterial or fungal infections necessitating use of antibiotics/antivirals/antifungal treatment (prophylaxis is acceptable).
- •Patients who are known to be positive or screened positive for hepatitis B (HBsAg positive) or C (anti-HCV positive).
- •Patients who are known to be positive or screened positive for the human immunodeficiency virus (HIV).
- •Patients with a family history of congenital or hereditary immunodeficiency.
- •Patients with a history of allergic reactions or hypersensitivity attributed to Human serum albumin or Plasma-lyte A.
- •Patient with history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis and/or active or acute exacerbation of chronic obstructive pulmonary disease (COPD).
- •Patients on supplemental home oxygen.
- •Patients with history of any autoimmune disease including, but not limited to inflammatory bowel disease (including ulcerative colitis and Crohn's Disease), systemic progressive sclerosis (scleroderma), systemic lupus erythematosus, autoimmune vasculitis (e.g., Wegener's granulomatosis), CNS or motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and myasthenia gravis, multiple sclerosis). Patients with Graves disease and vitiligo will be allowed.
- •Patients with a history of a malignancy other than the one evaluated in this study enrollment, with exception of the following circumstances:
- •Patients with a history of malignancy who have been adequately treated and have been disease-free for at least 1 year, and
- •Patients with adequately treated active non-invasive cancers (such as non-melanomatous skin cancer or in-situ bladder, cervical and breast cancers).
- •Patients with psychiatric/social situations or addictive disorders that may compromise the ability of the patients to give informed consent or to comply with the study procedures.
- •Female patients who are pregnant or lactating.
结局指标
主要结局
The occurrence of Dose-limiting toxicities (DLT) during the study treatment until 3 weeks after first NKR-2 study treatment administration.
时间窗: during the study treatment until 3 weeks after first NKR-2 study treatment administration.
Dose-limiting toxicity refers to a specific adverse event that is experienced during treatment and until 3 weeks after first NKR-2 dose administration, is new and at least possibly related to NKR-2 study treatment administered following a preconditioning regimen
次要结局
- Clinical activity secondary endpoints:The duration of response for patients with objective clinical response(From week 5 until Month 24.)
- Clinical activity secondary endpoints: The event-free survival (EFS) from the study enrollment.(From study enrollment until Month 24.)
- Mandatory correlative studies of this study are: The evaluation of NKG2D ligand expression in patients' tumor cells prior to and after treatment.(From day 1 until day 134 (week 19))
- Clinical activity secondary endpoints: The incidence of CR, CRMRD-, CRi, MLFS, PR, or SD for AML patients.(From week 5 until Month 24.)
- Clinical activity secondary endpoints: The overall survival (OS) from the study enrollment.(From study enrollment until Month 24.)
- The NKR-2 cell kinetics endpoint of this Phase I study is: The evaluation of the circulating NKR-2 peripheral blood kinetics post-administration.(From day 1 (visit 4) until the end of the administration phase (day 85 = week 12 = Visit 22).)
- Additional Safety Endpoint: the occurence of Adverse Events ans Serious Adverse Events and any toxicity linked to study participation until the end of the administration phase, and until the end of the treatment follow-up(Until the end of the administration phase, and until the end of the treatment follow-up (at Month 24 - Visit 34).)
- Clinical activity secondary endpoints: The objective clinical response rate (ORR) post the first NKR-2 administration(From week 5 until Month 24.)
- Clinical activity secondary endpoints: The relapse-free survival (RFS) from the study enrollment(From study enrollment until Month 24.)
- Clinical activity secondary endpoints: The cumulative incidence of death (CID)(From study enrollment until Month 24.)
- Clinical activity secondary endpoints: The non-relapse mortality (NMR) rate.(From study enrollment until Month 24.)
- Mandatory correlative studies of this study are: Characterization of systemic cytokine level release post NKR-2 administration.(From day 1 until day 134 (week 19))
- Mandatory correlative studies of this study are: The NKR-2 kinetics post-injection in the bone marrow.(From week 5 until month 24)
- Clinical activity secondary endpoints: The incidence of CR, PR, marrow CR, cytogenic response, hematologic improvement or SD for MDS patients(From week 5 until Month 24.)
- Clinical activity secondary endpoints: The ORR among subjects retreated with NKR-2.(From week 5 until Month 24.)
- Clinical activity secondary endpoints: The cumulative incidence of relapse (CIR)(From study enrollment until Month 24.)
- Clinical activity secondary endpoints: The duration of second response among subjects retreated with NKR-2.(From week 5 until Month 24.)
- Mandatory correlative studies of this study are: The evaluation of NKG2D ligand expression in patients' peripheral mononuclear cells prior to and after treatment.(From day 1 until day 134 (week 19))
研究者
研究点 (12)
Loading locations...
相似试验
Unknown
1 期
Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver MetastasesColon Cancer Liver MetastasisNCT03310008Celyad Oncology SA36
已完成
2 期
Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)X-Linked HypophosphatemiaNCT02750618Kyowa Kirin, Inc.13
招募中
2 期
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With MyelofibrosisMyelofibrosisNCT05037760Takeda135
招募中
2 期
Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry DiseaseFabry DiseaseNCT06114329AceLink Therapeutics, Inc.16
终止
1 期
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological MalignanciesAdvanced Nonhematological NeoplasmsNCT03370302Calithera Biosciences, Inc28